SCYNEXIS, Inc. (SCYX)

NCM – Real vaqt narxi. Valyuta: USD

3.85

+0.04 (1.05%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

3.92

+0.07 (1.82%)

Bozordan keyin: Jun 26, 2026, 7:42 PM EDT

22.05.2026

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026

11.05.2026

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today reported financial results for the first quarter ended March 31, 2026.

07.05.2026

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company's Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee's acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

31.03.2026

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

31.03.2026

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and certain rare diseases, today announced that it has entered into a definitive agreement with SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company A U.S. pharmaceutical company specializing in the deve.

31.03.2026

SCYNEXIS Announces $40.0 Million Private Placement

JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors. The Company anticipates upfront gross proceeds from the private placement to be approximately $40.0 million, before deducting placement agent fees and transaction-related expenses, and up to an additional $52.2 million in gross proceeds if the Common Warrants are fully exercised for cash, subject to Stockholder Approval of shares of common stock issuable upon exercise of the Common Warrants. The private placement is expected to close on or about April 1, 2026, subject to the satisfaction of customary closing conditions.

31.03.2026

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progression A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027 With this acquisition, SCYNEXIS strengthens its mission to develop innovative solutions for severe and rare diseases, unlocking further opportunities for value creation SCYNEXIS will host a conference call on March 31, 2026 at 8:30 a.m. ET to provide a corporate update.

Videolar

No Data

There is no data to display

Press-relizlar

22.05.2026

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026

11.05.2026

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

07.05.2026

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

31.03.2026

SCYNEXIS, Inc. (SCYX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

SCYNEXIS, Inc. (SCYX)

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

SCYNEXIS Announces $40.0 Million Private Placement

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Videolar

No Data

Press-relizlar

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

SCYNEXIS Announces $40.0 Million Private Placement

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Videolar

No Data

Press-relizlar

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

Search stocks

SCYNEXIS, Inc. (SCYX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

SCYNEXIS, Inc. (SCYX)

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

SCYNEXIS Announces $40.0 Million Private Placement

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Videolar

No Data

Press-relizlar

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

SCYNEXIS Announces $40.0 Million Private Placement

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Videolar

No Data

Press-relizlar

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million